<DOC>
	<DOCNO>NCT00443287</DOCNO>
	<brief_summary>The primary objective investigate patient suffer intermittent claudication due Fontaine stage II Peripheral Arterial Disease ( PAD ) whether 26-week treatment HMR1766 top clopidogrel may result improvement walking capacity , compare three dos HMR1766 placebo , calibrate effect versus cilostazol .</brief_summary>
	<brief_title>Efficacy Safety HMR1766 Patients With Fontaine Stage II Peripheral Arterial Disease</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Intermittent Claudication</mesh_term>
	<mesh_term>Cilostazol</mesh_term>
	<criteria>Patient stable symptom intermittent claudication low extremity , secondary chronic occlusive arterial disease atherosclerosis etiology ( symptoms present 6 month longer significantly change within past 3 month ) Initial claudication distance 30 250 meter screen constant workload treadmill test Confirmation underlie Peripheral Arterial Disease ( PAD ) screen Confirmation symptom stability randomization base constant workload treadmill test performance The patient must optimal cardiovascular risk prevention appropriate management PAD , include clopidogrel dose 75mg per day , study period Patient participate investigational clinical trial last month prior screen Pregnant breastfeed woman woman without document double birth control measure least 3 month prior randomization Symptoms PAD age 40 year Recent initiation discontinuation treatment vasoactive agent ( e.g. , pentoxifylline , berprost sodium , papverine , isoxsuprine , nylidrin , cyclandelate , niacin derivative ) . Patients treat cilostazol within 3 month prior screen also exclude Recent lowerextremity surgical endovascular arterial reconstruction sympathectomy , recent deep venous thrombosis Recent occurrence least one following : acute myocardial infarction , unstable angina , coronary artery bypass graft , percutaenous coronary intervention , transient ischemic attack stroke The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Peripheral</keyword>
	<keyword>Artery</keyword>
	<keyword>Disease</keyword>
</DOC>